An update on the use of lenalidomide for the treatment of multiple myeloma.
about
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Emerging antibodies for the treatment of multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionLenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
P2860
An update on the use of lenalidomide for the treatment of multiple myeloma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
An update on the use of lenalidomide for the treatment of multiple myeloma.
@en
type
label
An update on the use of lenalidomide for the treatment of multiple myeloma.
@en
prefLabel
An update on the use of lenalidomide for the treatment of multiple myeloma.
@en
P2860
P1476
An update on the use of lenalidomide for the treatment of multiple myeloma.
@en
P2093
Evangelos Terpos
Flora Zagouri
P2860
P304
P356
10.1517/14656566.2015.1067681
P407
P577
2015-07-13T00:00:00Z